Trial Profile
A Long-term Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca; Takeda
- 21 May 2016 New trial record